Company News
Wednesday preview: US Fed decision, Lloyds in focus
All eyes on Thursday would be on the US central bank as it announced its latest policy decision.
De La Rue appoints Nick Bray as interim chairman
Banknote printer De La Rue said on Tuesday that it has appointed Nick Bray as interim chairman.
BP posts $5bn Q1 profit as windfall tax debate reignites
The debate around windfall profits on energy companies was reignited on Tuesday when oil giant BP reported a better-than-expected first quarter profit of $5bn.
DuPont downgrades top end of FY sales guidance
DuPont downgraded its full-year sales guidance on Tuesday as it pointed to a delay in the recovery of the electronics market.
Pfizer reaffirms guidance after Q1 fall in Covid-19 revenue
Pharmaceutical giant Pfizer reported a year-on-year decline in earnings per share and revenue on Tuesday, primarily driven by an expected decrease in revenue from its Covid-19 vaccine product, ‘Comirnaty’.
Apollo drafts in former Coty CEO to help with THG offer - report
A former chief executive of Coty has reportedly been drafted in to help Apollo Global Management draw up a firm offer for health and beauty retailer THG.
Uber beats expectations on Q1 earnings, revenue
Uber Technologies shares were soaring in pre-market trading on Tuesday, after the car-hire and delivery giant beat market expectations on both first-quarter earnings and revenue.
Greatland adds Australian director ahead of possible ASX listing
Greatland Gold announced the appointment of Yasmin Broughton as an independent non-executive director on Tuesday, effective immediately.
Restaurant Group reports 'very encouraging' trading
The Restaurant Group reported "very encouraging" trading for the first four months of the year, putting it ahead of schedule to achieve its medium-term targets for increasing its margins and reducing its debt.
Alpha FMC acquires Sydney-based Shoreline for initial £4.2m
Alpha FMC announced the acquisition of Shoreline Consulting and Shoreline Consolidated on Tuesday, collectively known as ‘Shoreline’, for AUD 8m (£4. 2m) in cash.
Judges subsidiary acquires California cosmetics measuring firm
Scientific instrument company Judges Scientific announced on Tuesday that its subsidiary, Dia-Stron has acquired Bossa Nova Vision (BNV) for $1. 6m in cash.
PetroTal appoints experienced new operations manager
International oil and gas company PetroTal announced the appointment of José Contreras as its senior-vice president of operations on Tuesday, effective from 1 May.
Sylvania Platinum announces $10m share buyback programme
Sylvania Platinum announced its intention to conduct a share buyback programme on Tuesday, aiming to purchase ordinary shares on the market up to a maximum consideration of $10m.
Synectics updates market on Asia casino-resort project
Security and surveillance specialist Synectics updated the market on its new casino resort project in Asia on Tuesday.
Wizz Air passenger numbers, load factors rise in April
Low-cost airline Wizz Air carried 4,927,076 passengers in April, it said in its monthly update on Tuesday, representing a 32. 3% increase compared to the same month in 2022.
Pearson slides after Chegg warns over ChatGPT
Shares in education publisher Pearson slid on Tuesday after US firm Chegg, which provides online guidance for students preparing tests, warned over the impact of AI chatbots on its homework-help services.
Ashtead kicks off fresh $500m share buyback programme
Equipment rental company Ashtead Group announced the launch of a new share buyback programme on Tuesday, worth up to $500m.
Vianet set to top profit expectations for 2023 financial year
Internet of things (IoT)-focussed data and information specialist Vianet Group said in an update on Tuesday that it expects full-year turnover for the 2023 financial year to increase by 7% to more than £14m.
Mercia Asset Management upbeat on new fund raises
Mercia Asset Management announced on Tuesday that its existing managed funds had continued to attract new investments, while its new fund raises had been successful, totalling around £80m.
AstraZeneca 'disappointed' with FDA panel vote on prostate drug
AstraZeneca said it was disappointed with a decision by a panel of US Food and Drug Administration advisers to restrict use of its treatment for a type of prostate cancer.